OPTIMISE-CKD Study_Dapagliflozin effectiveness in CKD

Trial Identifier:	D169AR00037
Sponsor:	AstraZeneca
Start Date:	February 2026
Primary Completion Date:	May 2026
Study Completion Date:	May 2026
Condition:	Chronic Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Spain	Madrid, Spain, 28002

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.